Cancer Treatment and Pharmacology
Cancer Treatment and Pharmacology is a research topic within Oncology. Science Explorer counts 55k research works in it since 1950. 10.5% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the chemotherapy-induced peripheral neuropathy (CIPN) experienced by cancer patients, particularly in the context of breast cancer treatment. It covers various aspects such as the neurotoxic effects of taxanes and oxaliplatin, neuroprotective strategies, and the impact of CIPN on the quality of life of patients. Additionally, it discusses the use of microtubule-targeting agents like Eribulin Mesylate in cancer treatment.
- Chemotherapy-Induced Peripheral Neuropathy
- Taxanes
- Oxaliplatin
- Paclitaxel
- Neurotoxicity
- Metastatic Breast Cancer
- Eribulin Mesylate
- Neuroprotective Strategies
- Microtubule-Targeting Agents
- Quality of Life
- Research works
- 55k fractional, since 1950
- In the world top 10%
- 5.8k per year above
- Top-10% rate
- 10.5% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- -8% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Cancer Treatment and Pharmacology research?
By volume, the United States and China publish the most (1.8k and 918 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.8k works
- 2 China 918 works
- 3 Japan 415 works
- 4 India 331 works
- 5 France 274 works
- 6 Italy 252 works
- 7 United Kingdom 251 works
- 8 Germany 245 works
- 9 Spain 199 works
- 10 South Korea 157 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Cancer Treatment and Pharmacology research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Cancer Treatment and Pharmacology research, followed by Memorial Sloan Kettering Cancer Center and Chinese Academy of Medical Sciences & Peking Union Medical College.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer Center United States 62 works
- 2 Memorial Sloan Kettering Cancer Center United States 43 works
- 3 Chinese Academy of Medical Sciences & Peking Union Medical College China 36 works
- 4 University of North Carolina at Chapel Hill United States 36 works
- 5 Dana-Farber Cancer Institute United States 27 works
- 6 Mayo Clinic in Arizona United States 20 works
- 7 Harvard University United States 20 works
- 8 The Ohio State University United States 18 works
- 9 Fudan University Shanghai Cancer Center China 18 works
- 10 Sun Yat-sen University China 18 works
Who are the leading researchers in Cancer Treatment and Pharmacology?
The most-cited researchers publishing on Cancer Treatment and Pharmacology include Judith A. K. Howard.
- 1 Judith A. K. Howard 5.5k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Cancer Treatment and Pharmacology research done?
The largest centres of Cancer Treatment and Pharmacology research in 2022–2025 are Beijing (China), New York (United States), Tokyo (Japan) and Shanghai (China). Among places with at least 20 works in it, it is an unusually large share of all research in Scottsdale.
Largest cities, 2022–2025
Where it is the local speciality
- ScottsdaleUS · 20.9 works6.6×
Location quotient: how much more of its research is in Cancer Treatment and Pharmacology than the world average.
Where is the best place to study Cancer Treatment and Pharmacology?
Among universities, judged by research, Nanjing University of Chinese Medicine, Zagazig University and Chinese Academy of Medical Sciences & Peking Union Medical College score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Nanjing University of Chinese Medicine China | 51.2 | 27.2% | 5.0× | 8 | +109.9% |
| 2 | Zagazig University Egypt | 45.9 | 19.6% | 3.3× | 8 | +251.0% |
| 3 | Chinese Academy of Medical Sciences & Peking Union Medical College China | 39.5 | 8.2% | 5.9× | 36 | -8.7% |
| 4 | Harvard University United States | 39.5 | 17.7% | 2.5× | 20 | +9.5% |
| 5 | Cairo University Egypt | 38.5 | 19.6% | 2.1× | 11 | +93.1% |
| 6 | Medical College of Wisconsin United States | 36.6 | 8.1% | 7.2× | 12 | +74.9% |
| 7 | University of California, San Francisco United States | 36.2 | 18.2% | 3.5× | 14 | -14.5% |
| 8 | Emory University United States | 34.5 | 17.5% | 3.4× | 15 | -25.4% |
| 9 | Medical University of Vienna Austria | 34.2 | 14.0% | 4.9× | 10 | -2.6% |
| 10 | University of Michigan United States | 31.8 | 14.3% | 2.0× | 18 | +23.8% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Cancer Treatment and Pharmacology research growing?
Output in 2018–2022 was 8% lower than in 2013–2017, peaking in 2012. The fastest-growing topics are Cancer Treatment and Pharmacology.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.